Published by Global Markets Direct
on Nov 28, 2011
, 58 pages
PDF format - Delivered by Email within 1 day
7TM Pharma A/S - Product Pipeline Review - H2 2011
Global Market Direct's pharmaceuticals report, "7TM Pharma A/S - Product Pipeline Review - H2 2011" provides data on the 7TM Pharma A/S's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, 7TM Pharma A/S's corporate website, SEC filings, investor presentations and featured press releases, both from 7TM Pharma A/S and industry-specific third party sources, put together by Global Markets Direct's team.
- 7TM Pharma A/S - Brief 7TM Pharma A/S overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of 7TM Pharma A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of 7TM Pharma A/S with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the 7TM Pharma A/S's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate 7TM Pharma A/S's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of 7TM Pharma A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the 7TM Pharma A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with 7TM Pharma A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of 7TM Pharma A/S and identify potential opportunities in those areas.